Cardiff International (OTCQB:CDIF) said today that it has agreed to acquire MedicaMetrix as a subsidiary in an all-stock transaction valued at $6 million.
Delaware-based MedicaMetrix has developed a medical device, ProstaMetric, that enables more effective prostate cancer diagnosis and monitoring. The device won CE Mark clearance in the European Union in October last year and has no direct competitor, according to Cardiff.
Get the full story at our sister site, Medical Design & Outsourcing.